Current stage -Stage IV Posts on Medivizor
Navigation Menu

Current stage -Stage IV Posts on Medivizor

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Evaluating real-world outcomes of abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer

Posted by on Aug 7, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the real-world outcomes of two widely used drugs, abiraterone (Zytiga) and enzalutamide (Xtandi) in patients diagnosed with metastatic castrate-resistant prostate cancer (mCRPC). The study showed that both drugs were effective in these patients in a real-world setting, with better results...

Read More

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

Posted by on Jul 11, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with...

Read More

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

Posted by on Jun 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the...

Read More

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Read More

Searching for patients with advanced prostate cancer to trial an immunotherapy

Searching for patients with advanced prostate cancer to trial an immunotherapy

Posted by on Apr 30, 2021 in Prostate cancer | 0 comments

In a nutshell This trial is aiming to assess the effectiveness of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in treating metastatic prostate cancer according to the percentage of CD8 cells patients have. The main outcomes that are to be measured are the clinical benefit rate and the percentage of CD8 cells on biopsy during...

Read More

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Bicalutamide or enzalutamide: which is better with ADT in men with advanced prostate cancer?

Posted by on Mar 5, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness of bicalutamide (Casodex) to enzalutamide (Xtandi), both in combination with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). The comparison showed that enzalutamide with ADT improves the outcomes particularly in Black men with mHSPC.  Some...

Read More

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Evaluating the effectiveness and safety of stereotactic ablative body radiotherapy in advanced cancer

Posted by on Feb 26, 2021 in Melanoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of stereotactic ablative radiation therapy (SABR) in the treatment of patients with oligometastatic (few metastases) cancer. The data showed that the use of SABR in these patients was associated with high overall survival and low toxicity. Some background Oligometastatic cancer (OMC)...

Read More

Searching for patients with advanced prostate cancer to trial an experimental combination treatment.

Searching for patients with advanced prostate cancer to trial an experimental combination treatment.

Posted by on Dec 13, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is looking to examine the safety and effectiveness of a new drug called CYH33 in combination with olaparib (Lynparza) for the treatment of advanced solid tumors including prostate cancer. The main outcomes that are to be measured are side effects and the response rate to the treatment. This trial is being carried out in Houston,...

Read More

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Posted by on Nov 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...

Read More

Evaluating cabozantinib plus docetaxel and prednisone in patients with metastatic castration resistant prostate cancer

Evaluating cabozantinib plus docetaxel and prednisone in patients with metastatic castration resistant prostate cancer

Posted by on Nov 15, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of combining cabozantinib (Cabometyx) with docetaxel (Taxotere) and prednisone (Deltasone) in treating patients with metastatic castration-resistant prostate cancer (mCRPC). The main finding was that the combination was safe and could possibly be effective in such patients. Some background Docetaxel was the...

Read More

Searching for patients with advanced prostate cancer to trial a new immune treatment.

Searching for patients with advanced prostate cancer to trial a new immune treatment.

Posted by on Nov 8, 2020 in Prostate cancer | 0 comments

In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including prostate cancer. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated. These...

Read More